文献速递脊柱关节炎

Deucravacitinib治疗活动性银屑病关节炎的52周III期POETYK PsA-1试验结果

Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial.
PubMed 文献 · Ann Rheum Dis · 2026-08-07

这项随机双盲安慰剂对照III期试验纳入670例生物制剂初治的活动性银屑病关节炎患者,评估口服选择性TYK2抑制剂deucravacitinib的疗效与安全性。第16周deucravacitinib组ACR20应答率显著高于安慰剂组(54.2% vs 34.1%,P < .001),疗效至第52周进一步提升,且未发现新的安全信号。

要点

  • 第16周ACR20应答率deucravacitinib组54.2%,安慰剂组34.1%(P < .001)。
  • 52周内疗效持续提升,安慰剂转deucravacitinib者改善与持续用药者相似。
  • 严重不良事件发生率低,无心血管事件、恶性肿瘤或机会性感染失衡。

核心结论

  • Deucravacitinib在生物制剂初治的活动性银屑病关节炎患者中,临床应答、患者报告结局及结构损伤抑制均优于安慰剂,且耐受性和安全性良好。

研究设计与样本

  • 随机、双盲、安慰剂对照III期POETYK PsA-1试验,纳入670例对生物制剂改善病情抗风湿药初治的活动性银屑病关节炎成人患者,按1:1随机接受口服deucravacitinib 6 mg每日一次或安慰剂至第16周,随后继续deucravacitinib或由安慰剂转换至deucravacitinib至第52周。

主要发现

  • 第16周deucravacitinib组ACR20应答率显著高于安慰剂组(54.2% vs 34.1%,P < .001)。
  • deucravacitinib组应答在第52周增加,由安慰剂转换至deucravacitinib的患者改善与持续接受deucravacitinib者相似。
  • 第16周及第52周均观察到结构损伤抑制。
  • 第16周严重不良事件发生率deucravacitinib组1.8%、安慰剂组2.4%,因不良事件停药率分别为2.4%和1.8%,至第52周均保持低水平,心血管事件、恶性肿瘤或机会性感染无失衡。
  • 未检测到新的安全信号,无死亡发生。

临床怎么用

  • 对于生物制剂初治的活动性银屑病关节炎患者,deucravacitinib 6 mg每日一次可作为口服靶向治疗选择,治疗52周内持续获益且安全性良好。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The randomised, double-blind, placebo-controlled, phase 3 Program fOr Evaluation of TYK2 inhibitor Psoriatic Arthritis-1 (POETYK PsA-1) trial evaluated the efficacy, safety, and tolerability of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with PsA naïve to biologic disease-modifying antirheumatic drugs. METHODS: Adults with active PsA, high-sensitivity C-reactive protein concentration ≥ 3 mg/L, and ≥ 1 PsA-related hand and/or foot erosion detectable via radiograph were randomised 1:1 to oral deucravacitinib 6 mg once daily or placebo through week (W) 16. At W16, patients continued receiving deucravacitinib or switched from placebo to deucravacitinib through W52. The primary endpoint was American College of Rheumatology 20% improvement in response (ACR20) at W16. Nonresponder imputation was used for missing data. Efficacy and safety were evaluated through W52. Post hoc rank analysis of covariance was used to evaluate structural damage with no missing data imputation. RESULTS: In 670 patients, a significantly greater proportion of those receiving deucravacitinib vs placebo achieved ACR20 at W16 (54.2% vs 34.1%, P < .001). Responses with deucravacitinib were increased at W52. Patients who switched from placebo to deucravacitinib achieved improvements similar to those in patients who received continuous deucravacitinib. Inhibition of structural damage was observed at W16 and W52. At W16, incidences of serious adverse events (AEs) (deucravacitinib, 1.8%; placebo, 2.4%) and discontinuations due to AEs (2.4%; 1.8%) were low and remained low through W52, without imbalances in cardiovascular events, malignancies, or opportunistic infections. No new safety signals were detected; no deaths occurred. CONCLUSIONS: Deucravacitinib demonstrated superiority vs placebo for clinical responses, patient-reported outcomes, and structural damage inhibition in patients with PsA, with favourable tolerability and safety.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. van der Heijde D, Mease PJ, Paul C, et al. Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial. Ann Rheum Dis. 2026. PMID: 42562758. doi:10.1016/j.ard.2026.05.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。